Payment overview · 2025
General Payments
$321.94
12 reported records · 8 companies
Healthcare provider profile · identity verified
Abbass Hamze, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DEARBORN HEIGHTS, MI · NPI 1952945529
Verified facts
What the public records show
CMS Open Payments records show Abbass Hamze, NP received $321.94 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.95 | 34.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.41 | 19.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.09 | 10.6% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $33.00 | 10.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.29 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.74 | 7.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.96 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.50 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.94 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $109.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.99 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.09 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $33.00 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metformin Hcl | Metformin Hcl | 159 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 139 | 24 |
| Omeprazole | Omeprazole | 135 | 27 |
| Losartan Potassium | Losartan Potassium | 94 | 21 |
| Famotidine | Famotidine | 82 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 16 |
| Montelukast Sodium | Montelukast Sodium | 79 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 16 |
| Simvastatin | Simvastatin | 66 | suppressed |
| Ibuprofen | Ibuprofen | 65 | 21 |
| Lisinopril | Lisinopril | 64 | 13 |
| Meloxicam | Meloxicam | 63 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 12 |
| Amlodipine Besylate | Amlodipine Besylate | 58 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 13 |
| Alcohol Pads | Alcohol Antiseptic Pads | 49 | 14 |
| Azithromycin | Azithromycin | 45 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 17 |
| Potassium Chloride | Potassium Chloride | 40 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 12 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 11 |
| Naproxen | Naproxen | 28 | 13 |
| Prednisone | Prednisone | 28 | 22 |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Gabapentin | Gabapentin | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 14 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.94 · 12 records | Lilly USA, LLC | Cologuard Collection Kit, ELIQUIS, NURTEC ODT, Natroba, Ozempic, Spinosad, TRELEGY ELLIPTA, WaveWriter Alpha Prime 16, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error